All sponsors

RemeGen Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS30
PHASE 3 / 2-314
RECRUITING21
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO60%

Delay Index: of 10 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →

Open RemeGen Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Capecitabine
NCT06155383
P2RecruitingGastric Cancer; Gastroesophageal Junction Adenocarcinoma902025-01-31
Disitamab Vedotin for Injection
NCT06389006
P2RecruitingBreast Cancer792025-06-01
RC48-ADC(2.5mg/kg)
NCT05980481
P2/3Active, not recruitingGastric Cancer2012025-07-10 (+12 mo)
RC118-ADC
NCT05205850
P1/2RecruitingAdvanced Solid Tumor1352025-09-30
Disitamab Vedotin Injection (18 weeks)
NCT06227117
P2RecruitingBreast Cancer1202025-12
RC48-ADC in Combination with gemcitabine
NCT05943379
P2RecruitingNMIBC852025-12-01
RC148 Monotherapy
NCT06016062
P1/2RecruitingSolid Tumor2212025-12-31 (+12 mo)
RC108
NCT06962865
P2RecruitingNon-Small Cell Lung Cancer802026-05-31
Telitacicept
NCT05799287
P3Active, not recruitingPrimary IgA Nephropathy3182026-06 (+8 mo)
Disitamab Vedotin Injection
NCT06178159
P2RecruitingBreast Cancer402026-06 (+18 mo)
Disitamab Vedotin
NCT06642545
P2RecruitingBreast Cancer402026-10-01
Disitamab Vedotin Injection
NCT06221748
P2/3RecruitingGastric Cancer; Gastroesophageal Junction Adenocarcinoma902026-12
RC48-ADC
NCT05302284
P3RecruitingUrothelial Carcinoma; HER2-expressing4522026-12-31
Telitacicept
NCT07249632
P3RecruitingMyasthenia Gravis, Ocular1202026-12-31
RC148 (Dose 1) plus Capecitabine and Oxaliplatin
NCT07462143
P2/3RecruitingColorectal (Colon or Rectal) Cancer802027-05-12
Disitamab Vedotin
NCT06155396
P2RecruitingCervical Cancer1162027-06-30
Telisotuzumab adizutecan plus RC148(ABBV-1480)
NCT07874282
P2Not yet recruitingPatients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology2002027-12
RC48-ADC
NCT05745740
P1/2Not yet recruitingNon-small Cell Lung Cancer262027-12-01 (+24 mo)
RC278
NCT07105215
P1/2RecruitingSolid Tumors3122027-12-31
RC148 plus Carboplatin and Paclitaxel
NCT07416474
P3RecruitingNon-Small Cell Lung Cancer5742027-12-31
RC48-ADC
NCT04400695
P3RecruitingBreast Cancer3662027-12-31 (+62 mo)
Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
NCT06944496
P3Not yet recruitingGastric Carcinoma6162028-05-15
RC148 plus Telisotuzumab adizutecan
NCT07895355
P2Not yet recruitingPatients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy4122028-07
RC28-E
NCT07936487
P3Not yet recruitingDiabetic Macular Edema (DME); wAMD3502028-12-01
Disitamab Vedotin for injection
NCT06378242
P1/2RecruitingHigh-risk Non-muscle Invasive Bladder Cancer242029-03-15
Telitacicept
NCT07495033
P3Not yet recruitingCTD-ILD2602029-05-31
Disitamab Vedotin
NCT07315750
P3RecruitingGastric Carcinoma5552029-06-30
RC288 For Injection
NCT07537881
P1/2RecruitingSolid Tumors3262029-12-30
RC118(Dose 1) plus RC148(Dose 1)
NCT07935369
P2/3Not yet recruitingAdvanced Gastric or Gastroesophageal Junction Adenocarcinoma6802030-04-30
RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
NCT07829549
P3RecruitingPreviously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations5402031-04